PAI-1 and kidney fibrosis

Frontiers in Bioscience

Volumn 14, Issue 6, 2009, Pages 2028-2041

  Ma, Li Jun ^a   Fogo, Agnes B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aldosterone; Angiotensin; EMT; Kidney; PAI 1; Review; Thymosin 4

Indexed keywords

ANGIOTENSIN DERIVATIVE; OLIGOPEPTIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERASPENIDE; THYMOSIN; THYMOSIN BETA(4); TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; ANTIBODY SPECIFICITY; CHRONIC DISEASE; DISEASE MODEL; FIBROSIS; HUMAN; KIDNEY DISEASE; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSINS; ANIMALS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; FIBROSIS; HUMANS; KIDNEY DISEASES; MICE; OLIGOPEPTIDES; ORGAN SPECIFICITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENIN-ANGIOTENSIN SYSTEM; THYMOSIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 63849095053     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3361     Document Type: Article

References (129)

1. Loskutoff DJ, TS Edgington: An inhibitor of plasminogen activator in rabbit endothelial cells. J Biol Chem 256:4142-4145 (1981).
2. Lijnen HR: Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 3:35-45 (2005). (Pubitemid 41647113)
3. Dellas C, DJ Loskutoff: Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 93:631-640 (2005). (Pubitemid 40485397)
4. Shik J, PS Parfrey: The clinical epidemiology of cardiovascular disease in chronic kidney disease. Curr Opin Nephrol Hypertens 14:550-557 (2005). (Pubitemid 41531846)
5. Menon V, A Gul, MJ Sarnak: Cardiovascular risk factors in chronic kidney disease. Kidney Int 68:1413-1418 (2005). (Pubitemid 43169885)
6. Wali RK, WL Henrich: Chronic kidney disease: a risk factor for cardiovascular disease. Cardiol Clin 23:343-362 (2005).
7. Vaughan DE: PAI-1 and atherothrombosis. J Thromb Haemost 3:1879-1883 (2005). (Pubitemid 41716575)
8. de Boer JP, JJ Abbink, MC Brouwer, C Meijer, D Roem, GP Voorn, JW Lambers, JA van Mourik, CE Hack: PAI-1 synthesis in the human hepatoma cell line HepG2 is increased by cytokines-evidence that the liver contributes to acute phase behaviour of PAI-1. Thromb Haemost 65:181-185 (1991).
9. Pandey M, DJ Loskutoff, F Samad: Molecular mechanisms of tumor necrosis factor-alpha-mediated plasminogen activator inhibitor-1 expression in adipocytes. Faseb J 19:1317-1319 (2005). (Pubitemid 41113735)
10. Eddy AA, AB Fogo: Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 17:2999-3012 (2006). (Pubitemid 44707760)
11. Revelo MP, C Federspiel, H Helderman, AB Fogo: Chronic allograft nephropathy: expression and localization of PAI-1 and PPAR-gamma. Nephrol Dial Transplant 20:2812-2819 (2005). (Pubitemid 41672284)
12. Delarue F, A Hertig, C Alberti, C Vigneau, M Ammor, J Berrou, K Akposso, MN Peraldi, E Rondeau, JD Sraer: Prognostic value of plasminogen activator inhibitor type 1 mRNA in microdissected glomeruli from transplanted kidneys. Transplantation 72:1256-1261 (2001). (Pubitemid 33026605)
13. Paueksakon P, MP Revelo, LJ Ma, C Marcantoni, AB Fogo: Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy. Kidney Int 61:2142-2148 (2002). (Pubitemid 34539331)
14. Kimura H, F Gejyo, Y Suzuki, S Suzuki, R Miyazaki, M Arakawa: Effects of polymorphisms in angiotensin converting enzyme and plasminogen activator-1 genes on the development of diabetic nephropathy and macroangiopathy. Kidney Int 54:1659-1669 (1998). (Pubitemid 28502908)
15. Reis K, T Arinsoy, U Derici, S Gonen, Z Bicik, O Soylemezoglu, U Yasavul, E Hasanoglu, S Sindel: Angiotensinogen and plasminogen activator inhibitor-1 gene polymorphism in relation to chronic allograft dysfunction. Clin Transplant 19:10-14 (2005). (Pubitemid 40227845)
16. Sawathiparnich P, LJ Murphey, S Kumar, DE Vaughan, NJ Brown: Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. J Clin Endocrinol Metab 88:3867-3873 (2003). (Pubitemid 37034540)
17. Ishikawa A, N Ohta, S Ozono, K Kawabe, T Kitamura: Inhibition of plasminogen activator inhibitor-1 by angiotensin II receptor blockers on cyclosporinetreated renal allograft recipients. Transplant Proc 37:994-996 (2005). (Pubitemid 40590770)
18. Lahlou A, MN Peraldi, E Thervet, A Flahault, F Delarue, F Soubrier, J Rossert, A Hertig, E Rondeau: Chronic graft dysfunction in renal transplant patients: potential role of plasminogen activator inhibitor type 1. Transplantation 73:1290-1295, 2002. (Pubitemid 34454278)
19. Nicholas SB, E Aguiniga, Y Ren, J Kim, J Wong, N Govindarajan, M Noda, W Wang, Y Kawano, A Collins, WA Hsueh: Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 67:1297-1307 (2005). (Pubitemid 40463106)
20. Collins SJ, SL Alexander, JM Lopez-Guisa, X Cai, R Maruvada, SC Chua, G Zhang, DM Okamura, S Matsuo, AA Eddy: Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice. Nephron Exp Nephrol 104:e23-34 (2006).
21. Fujisawa G, K Okada, S Muto, N Fujita, N Itabashi, E Kusano, S Ishibashi: Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 66:1493-1502 (2004). (Pubitemid 39298382)
22. Ma LJ, SL Mao, KL Taylor, T Kanjanabuch, Y Guan, Y Zhang, NJ Brown, LL Swift, OP McGuinness, DH Wasserman, DE Vaughan, AB Fogo: Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53:336-346 (2004). (Pubitemid 38174548)
23. Liang X, T Kanjanabuch, SL Mao, CM Hao, YW Tang, PJ Declerck, AH Hasty, DH Wasserman, AB Fogo, LJ Ma: Plasminogen activator inhibitor-1 modulates adipocyte differentiation. Am J Physiol Endocrinol Metab 290:E103-E113 (2006).
24. Eddy AA: Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 283:F209-220 (2002). (Pubitemid 34778983)
25. Takeshita K, K Yamamoto, M Ito, T Kondo, T Matsushita, M Hirai, T Kojima, M Nishimura, Y Nabeshima, DJ Loskutoff, H Saito, T Murohara: Increased expression of plasminogen activator inhibitor-1 with fibrin deposition in a murine model of aging, "Klotho" mouse. Semin Thromb Hemost 28:545-554 (2002).
26. Brown NJ, DE Vaughan, AB Fogo: The rennin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease. Semin Nephrol 22:399-406 (2002). (Pubitemid 35024516)
27. Brown NJ, KS Kim, YQ Chen, LS Blevins, JH Nadeau, SG Meranze, DE Vaughan: Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 85:336-344 (2000). (Pubitemid 32268835)
28. Nakamura S, I Nakamura, L-J Ma, DE Vaughan, AB Fogo: Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 58:251-259, 2000. (Pubitemid 30429870)
29. Ma LJ, T Naito, JY Han, AB Fogo: Plasminogen activator inhibitor-1 (PAI-1) deficiency prevents the development of glomerulosclerosis in the subtotal nephrectomy (5/6 Nx) in the mouse. J Am Soc Nephrol 16: 653A (2005).
30. Naito T, G Rodriguez, D-B Borza, LJ Ma, A Pozzi, AB Fogo: Podocyte PAI-1 affects angiotensin II (AngII)-induced ECM accumulation. Lab Invest 86:264A (2006).
31. Weisberg AD, F Albornoz, JP Griffin, DL Crandall, H Elokdah, AB Fogo, DE Vaughan, NJ Brown: Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol 25:365-371 (2005). (Pubitemid 40189159)
32. Kaikita K, AB Fogo, LJ Ma, JA Schoenhard, NJ Brown, DE Vaughan: Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 104:839-844 (2001). (Pubitemid 32762685)
33. Kaikita K, JA Schoenhard, CA Painter, RT Ripley, NJ Brown, AB Fogo, DE Vaughan: Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition. J Mol Cell Cardiol 34:617-627 (2002). (Pubitemid 35222847)
34. Oda T, HG Kim, D Wing, J Lopez-Guisa, S Jernigan, AA Eddy: Effects of genetic PAI-1 deficiency in mice with protein-overload proteinuria. J Am Soc Nephrol 10:578A (1999).
35. Sharma K, FN Ziyadeh: The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol 266:F829-F842 (1994).
36. Huang Y, S Wongamorntham, J Kasting, D McQuillan, RT Owens, L Yu, NA Noble, W Border: Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin IIindependent mechanisms. Kidney Int 69:105-113 (2006). (Pubitemid 43117745)
37. Yu L, WA Border, I Anderson, M McCourt, Y Huang, NA Noble: Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int 66:1774-1784 (2004). (Pubitemid 41094301)
38. Lyons RM, LE Gentry, AF Purchio, HL Moses: Mechanism of activation of latent recombinant transforming growth factor-beta 1 by plasmin. J Cell Biol 110:1361-1367 (1990).
39. Schultz-Cherry S, H Chen, DF Mosher, TM Misenheimer, HC Krutzsch, DD Roberts, JE Murphy-Ullrich: Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J Biol Chem 270:7304-7310 (1995).
40. Arend LJ, AM Smart, JP Briggs: Mouse beta (6) integrin sequence, pattern of expression, and role in kidney development. J Am Soc Nephrol 11:2297-2305 (2000).
41. Munger JS, X Huang, H Kawakatsu, MJ Griffiths, SL Dalton, J Wu, JF Pittet, N Kaminski, C Garat, MA Matthay, DB Rifkin, D Sheppard: The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96:319-328 (1999). (Pubitemid 29077586)
42. Ma LJ, HC Yang, A Gaspert, G Carlesso, MM Barty, JM Davidson, D Sheppard, AB Fogo: Transforming growth factor β (TGF-β) dependent and independent pathways of induction of tubulointerstitial fibrosis in αvβ6-/- mice. Am J Pathol 163:1261-1273 (2003). (Pubitemid 37175076)
43. Krag S, CC Danielsen, P Carmeliet, J Nyengaard, L Wogensen: Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-beta1-induced kidney disease. Kidney Int 68:2651-2666 (2005). (Pubitemid 43251011)
44. Shull MM, I Ormsby, AB Kier, S Pawlowski, RJ Diebold, M Yin, R Allen, C Sidman, G Proetzel, D Calvin: Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359:693-699 (1992).
45. Aoki CA, AT Borchers, M Li, RA Flavell, CL Bowlus, AA Ansari, ME Gershwin: Transforming growth factor beta (TGF-beta) and autoimmunity. Autoimmun Rev 4:450-459 (2005). (Pubitemid 41219324)
46. Ma LJ, S Jha, H Ling, A Pozzi, S Ledbetter, AB Fogo: Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats. Kidney Int 65:106-115 (2004). (Pubitemid 38037495)
47. Eitzman DT, RD McCoy, X Zheng, WP Fay, T Shen, D Ginsburg, RH Simon: Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97:232-237 (1996). (Pubitemid 26021713)
48. Hattori N, JL Degen, TH Sisson, H Liu, BB Moore, RG Pandrangi, RH Simon, AF Drew: Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 106:1341-1350 (2000).
49. Kitching AR, SR Holdsworth, VA Ploplis, EF Plow, D Collen, P Carmeliet, PG Tipping: Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med 185:963-968 (1997). (Pubitemid 27119880)
50. Oda T, YO Jung, HS Kim, X Cai, JM Lopez-Guisa, Y Ikeda, AA Eddy: PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60:587-596 (2001). (Pubitemid 32678902)
51. Matsuo S, JM Lopez-Guisa, X Cai, DM Okamura, CE Alpers, RE Bumgarner, MA Peters, G Zhang, AA Eddy: Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int 67:2221-2238 (2005). (Pubitemid 41623383)
52. Redmond EM, JP Cullen, PA Cahill, JV Sitzmann, S Stefansson, DA Lawrence, SS Okada: Endothelial cells inhibit flow-induced smooth muscle cell migration: role of plasminogen activator inhibitor-1. Circulation 103:597-603 (2001). (Pubitemid 32116247)
53. Proia RR, PR Nelson, MJ Mulligan-Kehoe, RJ Wagner, AJ Kehas, RJ Powell: The effect of endothelial cell overexpression of plasminogen activator inhibitor-1 on smooth muscle cell migration. J Vasc Surg 36:164-171 (2002). (Pubitemid 41122906)
54. Fogo AB: Renal fibrosis: not just PAI-1 in the sky. J Clin Invest 112:326-328 (2003). (Pubitemid 38063760)
55. Herz J, DK Strickland: LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 108:779-784 (2001). (Pubitemid 32880284)
56. Czekay RP, K Aertgeerts, SA Curriden, DJ Loskutoff: Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 160:781-791 (2003). (Pubitemid 36298272)
57. Degryse B, JG Neels, RP Czekay, K Aertgeerts, Y Kamikubo, DJ Loskutoff: The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chem 279:22595-22604 (2004). (Pubitemid 38679460)
58. Cao C, DA Lawrence, Y Li, CA Von Arnim, J Herz, EJ Su, A Makarova, BT Hyman, DK Strickland, L Zhang: Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. Embo J 25:1860-1870 (2006).
59. Czekay RP, DJ Loskutoff: Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp Biol Med (Maywood) 229:1090-1096 (2004). (Pubitemid 39602250)
60. Huang Y, M Haraguchi, DA Lawrence, WA Border, L Yu, NA Noble: A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 112:379-388 (2003). (Pubitemid 38063766)
61. Omasu F, T Oda, M Yamada, N Yoshizawa, K Yamakami, Y Sakurai, S Miura: Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats. Am J Physiol Renal Physiol 293:F1292-F1298 (2007). (Pubitemid 47583964)
62. Yamaguchi I, JM Lopez-Guisa, X Cai, SJ Collins, DM Okamura, AA Eddy: Endogenous urokinase lacks antifibrotic activity during progressive renal injury. Am J Physiol Renal Physiol 293:F12-19 (2007). (Pubitemid 47344995)
63. Zhang G, KA Kernan, SJ Collins, X Cai, JM Lopez-Guisa, JL Degen, Y Shvil, AA Eddy: Plasmin (ogen) promotes renal interstitial fibrosis by promoting epithelialto-mesenchymal transition: role of plasmin-activated signals. J Am Soc Nephrol 18:846-859 (2007). (Pubitemid 46434501)
64. Li Q, Y Laumonnier, T Syrovets, T Simmet: Plasmin triggers cytokine induction in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 27:1383-1389 (2007). (Pubitemid 46809429)
65. Fitzpatrick SL, G Kassam, KS Choi, HM Kang, DK Fogg, DM Waisman: Regulation of plasmin activity by annexin II tetramer. Biochemistry 39:1021-1028 (2000). (Pubitemid 30075329)
66. Laumonnier Y, T Syrovets, L Burysek, T Simmet: Identification of the annexin A2 heterotetramer as a receptor for the plasmin-induced signaling in human peripheral monocytes. Blood 107:3342-3349, 2006.
67. Kim J, KA Hajjar: Annexin II: a plasminogenplasminogen activator co-receptor. Front Biosci 7:d341-348 (2002).
68. Kumar V, G Farell, S Deganello, JC Lieske: Annexin II is present on renal epithelial cells and binds calcium oxalate monohydrate crystals. J Am Soc Nephrol 14:289-297 (2003). (Pubitemid 36150851)
69. Cheng CW, A Rifai, SM Ka, HA Shui, YF Lin, WH Lee, A Chen: Calcium-binding proteins annexin A2 and S100A6 are sensors of tubular injury and recovery in acute renal failure. Kidney Int 68:2694-2703 (2005). (Pubitemid 43251014)
70. Kalluri R, EG Neilson: Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112:1776-1784 (2003). (Pubitemid 38063698)
71. Yang J, RW Shultz, WM Mars, RE Wegner, Y Li, C Dai, K Nejak, Y Liu: Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 110:1525-1538 (2002). (Pubitemid 35396923)
72. Hu K, J Yang, S Tanaka, SL Gonias, WM Mars, Y Liu: Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem 281:2120-2127 (2006). (Pubitemid 43845801)
73. Hu K, C Wu, WM Mars, Y Liu: Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signaling. J Clin Invest 117:3821-3832 (2007). (Pubitemid 350224092)
74. Edgtton KL, RM Gow, DJ Kelly, P Carmeliet, AR Kitching: Plasmin is not protective in experimental renal interstitial fibrosis. Kidney Int 66:68-76 (2004). (Pubitemid 38870083)
75. Swaisgood CM, EL French, C Noga, RH Simon, VA Ploplis: The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Am J Pathol 157:177-187 (2000). (Pubitemid 30641735)
76. Ma J, A Weisberg, JP Griffin, DE Vaughan, AB Fogo, NJ Brown: Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int 69:1064-1072 (2006). (Pubitemid 43372182)
77. Huff T, O Rosorius, AM Otto, CS Muller, E Ballweber, E Hannappel, HG Mannherz: Nuclear localisation of the G-actin sequestering peptide thymosin beta4. J Cell Sci 117:5333-5341 (2004).
78. Mora CA, CA Baumann, JE Paino, AL Goldstein, M Badamchian: Biodistribution of synthetic thymosin beta 4 in the serum, urine, and major organs of mice. Int J Immunopharmacol 19:1-8 (1997). (Pubitemid 27259663)
79. Huff T, AM Otto, CS Muller, M Meier, E Hannappel: Thymosin beta4 is released from human blood platelets and attached by factor XIIIa (transglutaminase) to fibrin and collagen. Faseb J 16:691-696 (2002). (Pubitemid 34465433)
80. Sosne G, L Xu, L Prach, LK Mrock, HK Kleinman, JJ Letterio, LD Hazlett, M Kurpakus-Wheater: Thymosin beta 4 stimulates laminin-5 production independent of TGF-beta. Exp Cell Res 293:175-183 (2004). (Pubitemid 38064424)
81. Bock-Marquette I, A Saxena, MD White, JM Dimaio, D Srivastava: Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 432:466-472 (2004). (Pubitemid 39576522)
82. Smart N, CA Risebro, AA Melville, K Moses, RJ Schwartz, KR Chien, PR Riley: Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature 445:177-182 (2007). (Pubitemid 46095717)
83. Xu BJ, Y Shyr, X Liang, LJ Ma, EM Donnert, JD Roberts, X Zhang, V Kon, NJ Brown, RM Caprioli, AB Fogo: Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. J Am Soc Nephrol 16:2967-2975 (2005). (Pubitemid 44743494)
84. Orhan D, EM Donnert, BJ Xu, A Gaspert, J Ma, AB Fogo: Thymosin β-4 is increased in renal interstitial fibrosis. Lab Invest 87:274A (2007).
85. Potthoff SA, Y Zuo, L-J Ma, AB Fogo: Angiotensin II-induced Restored Fibrosis in β6 -/- mice is Linked to Thymosin β-4. J Am Soc Nephrol 18:419A (2007).
86. Azizi M, E Ezan, L Nicolet, JM Grognet, J Menard: High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition. Hypertension 30:1015-1019 (1997). (Pubitemid 27476151)
87. Azizi M, A Rousseau, E Ezan, TT Guyene, S Michelet, JM Grognet, M Lenfant, P Corvol, J Menard: Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 97:839-844 (1996). (Pubitemid 26060543)
88. Peng H, OA Carretero, N Vuljaj, TD Liao, A Motivala, EL Peterson, NE Rhaleb: Angiotensin-converting enzyme inhibitors: a new mechanism of action. Circulation 112:2436-2445 (2005). (Pubitemid 41504493)
89. Kanasaki K, D Koya, T Sugimoto, M Isono, A Kashiwagi, M Haneda: N-Acetyl-seryl-aspartyl-lysylproline inhibits TGF-beta-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells. J Am Soc Nephrol 14:863-872 (2003). (Pubitemid 36359268)
90. Wang D, OA Carretero, XY Yang, NE Rhaleb, YH Liu, TD Liao, XP Yang: N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo. Am J Physiol Heart Circ Physiol 287:H2099-2105 (2004).
91. Omata M, H Taniguchi, D Koya, K Kanasaki, R Sho, Y Kato, R Kojima, M Haneda, N Inomata: N-acetyl-sery-laspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established antiglomerular basement membrane nephritis. J Am Soc Nephrol 17:674-685 (2006).
92. Shibuya K, K Kanasaki, M Isono, H Sato, M Omata, T Sugimoto, S Araki, K Isshiki, A Kashiwagi, M Haneda, D Koya: N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice. Diabetes 54:838-845 (2005). (Pubitemid 40322089)
93. Rasoul S, OA Carretero, H Peng, MA Cavasin, J Zhuo, A Sanchez-Mendoza, DR Brigstock, NE Rhaleb: Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension. J Hypertens 22:593-603 (2004). (Pubitemid 38368494)
94. Peng H, OA Carretero, DR Brigstock, N Oja-Tebbe, NE Rhaleb: Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension. Hypertension 42:1164-1170 (2003). (Pubitemid 37549072)
95. Zuo YQ, SA Potthoff, PR Tennant, HC Yang, LJ Ma, AB Fogo: Synergistic Effects of AcSDKP and Angiotensin Receptor Blocker on Repressing Thymosin β4 (Thyβ4) Expression in Early Renal Interstitial Fibrosis. J Am Soc Nephrol 18:202A (2007).
96. Fogo AB: Progression and potential regression of glomerulosclerosis (Nephrology Forum). Kidney Int 59:804-819 (2001). (Pubitemid 32157952)
97. Fogo AB: Can glomerulosclerosis be reversed? Nat Clin Pract Nephrol 2:290-291 (2006). (Pubitemid 44058943)
98. Ma LJ, S Nakamura, JS Whitsitt, C Marcantoni, JM Davidson, AB Fogo: Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int 58:2425-2436 (2000).
99. Adamczak M, ML Gross, J Krtil, A Koch, K Tyralla, K Amann, E Ritz: Reversal of glomerulosclerosis after highdose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 14:2833-2842 (2003). (Pubitemid 37305646)
100. Adamczak M, ML Gross, K Amann, E Ritz: Reversal of glomerular lesions involves coordinated restructuring of glomerular microvasculature. J Am Soc Nephrol 15:3063-3072 (2004). (Pubitemid 39578838)
101. Zoja C, D Corna, D Camozzi, D Cattaneo, D Rottoli, C Batani, C Zanchi, M Abbate, G Remuzzi: How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 13:2898-2908 (2002). (Pubitemid 35386909)
102. Boffa JJ, Y Lu, S Placier, A Stefanski, JC Dussaule, C Chatziantoniou: Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 14:1132-1144 (2003). (Pubitemid 36514656)
103. Ma LJ, S Nakamura, JC Aldigier, M Rossini, H Yang, X Liang, I Nakamura, C Marcantoni, AB Fogo: Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 16:966-976 (2005). (Pubitemid 41710307)
104. Fujihara CK, M Velho, DM Malheiros, R Zatz: An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int 67:1913-1924 (2005). (Pubitemid 40577727)
105. Brown NJ, S Nakamura, LJ Ma, I Nakamura, E Donnert, M Freeman, DE Vaughan, AB Fogo: Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58:1219-1227 (2000).
106. Aldigier JC, T Kanjanbuch, LJ Ma, NJ Brown, AB Fogo: Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 16:3306-3314 (2005). (Pubitemid 46187550)
107. Eremina V, M Sood, J Haigh, A Nagy, G Lajoie, N Ferrara, HP Gerber, Y Kikkawa, JH Miner, SE Quaggin: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111:707-716 (2003). (Pubitemid 36278589)
108. Satchell SC, PW Mathieson: Angiopoietins: microvascular modulators with potential roles in glomerular pathophysiology. J Nephrol 16:168-178 (2003). (Pubitemid 37304072)
109. Salmon AH, I Toma, A Sipos, PR Muston, SJ Harper, DO Bates, CR Neal, J Peti-Peterdi: Evidence for restriction of fluid and solute movement across the glomerular capillary wall by the subpodocyte space. Am J Physiol Renal Physiol 293:F1777-F1786 (2007). (Pubitemid 350179602)
110. Kang DH, J Hughes, M Mazzali, GF Schreiner, RJ Johnson: Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 12:1448-1457 (2001). (Pubitemid 32666327)
111. Scruggs B, E Donnert, L-J Ma, J Bertram, AB Fogo: Capillary branching contributes to regression of sclerosis by angiotensin receptor blocker (ARB). J Am Soc Nephrol 16:674A (2005).
112. Liang XB, LJ Ma, T Naito, Y Wang, M Madaio, R Zent, A Pozzi, AB Fogo: Angiotensin type 1 receptor blocker restores podocyte potential to promote glomerular endothelial cell growth. J Am Soc Nephrol 17:1886-1895 (2006). (Pubitemid 44036173)
113. Ma LJ, AB Fogo: Role of angiotensin II in glomerular injury. Semin Nephrol 21:544-553 (2001). (Pubitemid 33094464)
114. Turner AJ, JA Hiscox, NM Hooper: ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci 25:291-294 (2004). (Pubitemid 38692418)
115. Ferrario CM, MC Chappell: Novel angiotensin peptides. Cell Mol Life Sci 61:2720-2727 (2004). (Pubitemid 40022433)
116. Nguyen G: The (pro)renin receptor: pathophysiological roles in cardiovascular and renal pathology. Curr Opin Nephrol Hypertens 16:129-133 (2007).
117. Kaschina E, T Unger: Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 12:70-88 (2003).
118. Ruiz-Ortega M, V Esteban, Y Suzuki, M Ruperez, S Mezzano, L Ardiles, P Justo, A Ortiz, J Egido: Renal expression of angiotensin type 2 (AT2) receptors during kidney damage. Kidney Int Suppl 64:S21-S26 (2003). (Pubitemid 37159623)
119. Abadir PM, RM Carey, HM Siragy: Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice. Hypertension 42:600-604 (2003). (Pubitemid 37237360)
120. Wolf G: "The road not taken": role of angiotensin II type 2 receptor in pathophysiology. Nephrol Dial Transplant 17:195-198 (2002). (Pubitemid 34157126)
121. Wolf G, FN Ziyadeh, F Thaiss, J Tomaszewski, RJ Caron, U Wenzel, G Zahner, U Helmchen, RA Stahl: Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J Clin Invest 100:1047-1058 (1997). (Pubitemid 27386288)
122. Ma J, H Nishimura, AB Fogo, V Kon, T Inagami, I Ichikawa: Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int 53:937-944 (1998). (Pubitemid 28155667)
123. Ohkubo N, H Matsubara, Y Nozawa, e al: Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 96:3954-3962 (1997).
124. Hashimoto N, Y Maeshima, M Satoh, M Odawara, H Sugiyama, N Kashihara, H Matsubara, Y Yamasaki, H Makino: Overexpression of angiotensin type 2 receptor ameliorates glomerular injury in a mouse remnant kidney model. Am J Physiol Renal Physiol 286:F516-525 (2004). (Pubitemid 38233646)
125. Naito T, LJ Ma, E Donnert, AB Fogo: Angiotensin type 2 receptor antagonist (AT2RA) worsens glomerulosclerosis in the rat remnant kidney model. J Am Soc Nephrol 16:654A (2005).
126. Cao Z, F Bonnet, R Candido, SP Nesteroff, WC Burns, H Kawachi, F Shimizu, RM Carey, M De Gasparo, ME Cooper: Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol 13:1773-1787 (2002). (Pubitemid 34700602)
127. Kouyama R, T Suganami, J Nishida, M Tanaka, T Toyoda, M Kiso, T Chiwata, Y Miyamoto, Y Yoshimasa, A Fukamizu, M Horiuchi, Y Hirata, Y Ogawa: Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 146:3481-3489 (2005). (Pubitemid 41065022)
128. van Dielen FM, WA Buurman, M Hadfoune, J Nijhuis, JW Greve: Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. J Clin Endocrinol Metab 89:4062-4068 (2004). (Pubitemid 39071514)
129. Bruun JM, JW Helge, B Richelsen, B Stallknecht: Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am J Physiol Endocrinol Metab 290:E961-967 (2006).